ATE432993T1 - Tar rna bindende peptide - Google Patents

Tar rna bindende peptide

Info

Publication number
ATE432993T1
ATE432993T1 AT00968684T AT00968684T ATE432993T1 AT E432993 T1 ATE432993 T1 AT E432993T1 AT 00968684 T AT00968684 T AT 00968684T AT 00968684 T AT00968684 T AT 00968684T AT E432993 T1 ATE432993 T1 AT E432993T1
Authority
AT
Austria
Prior art keywords
methods
screening
rna
compounds
dye
Prior art date
Application number
AT00968684T
Other languages
English (en)
Inventor
Tariq Rana
Original Assignee
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of ATE432993T1 publication Critical patent/ATE432993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
AT00968684T 1999-10-04 2000-10-04 Tar rna bindende peptide ATE432993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15764699P 1999-10-04 1999-10-04
PCT/US2000/027389 WO2001025486A1 (en) 1999-10-04 2000-10-04 Methods for identifying rna binding compounds

Publications (1)

Publication Number Publication Date
ATE432993T1 true ATE432993T1 (de) 2009-06-15

Family

ID=22564644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968684T ATE432993T1 (de) 1999-10-04 2000-10-04 Tar rna bindende peptide

Country Status (8)

Country Link
US (5) US6503713B1 (de)
EP (3) EP1218544B1 (de)
JP (2) JP2003511362A (de)
AT (1) ATE432993T1 (de)
AU (2) AU7856600A (de)
CA (2) CA2386239A1 (de)
DE (1) DE60042338D1 (de)
WO (2) WO2001025188A1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US7029846B2 (en) * 2000-10-04 2006-04-18 University Of Medicine And Dentistry Of New Jersey Site-specific protein modification
WO2002083837A1 (en) * 2001-04-11 2002-10-24 Ptc Therapeutics, Inc. Methods for identifying small molecules that bind specific rna structural motifs
US20060228730A1 (en) * 2001-04-11 2006-10-12 Rando Robert F Methods for identifying small molecules that bind specific RNA structural motifs
US6649573B2 (en) * 2001-04-13 2003-11-18 Michael J. Mitrovich Solid lubricant and composition
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
EP1451588A4 (de) * 2001-11-06 2005-03-09 Agilix Corp Empfindliche codierte nachweissysteme
WO2003062388A2 (en) * 2002-01-16 2003-07-31 The Regents Of The University Of California Inhibition of rna function
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US20040018495A1 (en) * 2002-07-24 2004-01-29 Xing-Xiang Li Microparticle based signal amplification for the detection of analytes
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3479838A1 (de) * 2003-02-04 2019-05-08 Cornell Research Foundation, Inc. Verwendung von aromatisch kationischem peptid
JP2006521116A (ja) * 2003-03-27 2006-09-21 ピーティーシー セラピューティクス，インコーポレーテッド 抗真菌性および／または抗増殖性分子を同定するためのｔＲＮＡスプライシング経路の酵素の標的化
WO2004087070A2 (en) * 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-FUNGAL AGENTS
US20070020630A1 (en) * 2003-03-27 2007-01-25 Trotta Christopher R Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-proliferative agents
EP1625149B1 (de) 2003-05-01 2016-02-17 Cornell Research Foundation, Inc. Verfahren und trägerkomplexe zum transport von molekülen zu zellen
AU2004236740A1 (en) * 2003-05-02 2004-11-18 Sigma-Aldrich Co. Solid phase cell lysis and capture platform
JP4990621B2 (ja) 2003-07-02 2012-08-01 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａプロセシングタンパク質複合体及びその使用
US20050064470A1 (en) * 2003-07-17 2005-03-24 Rana Tariq M. High throughput screening methods for identifying RNA binding compounds
WO2006011919A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
ES2327340T3 (es) * 2003-09-11 2009-10-28 Idexx Laboratories, Inc. Procedimiento y dispositivo para detectar el virus de la inmunodeficiencia felina.
CA2550264C (en) * 2003-12-18 2011-06-28 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2005077125A2 (en) * 2004-02-11 2005-08-25 Applera Corporation Methods and compositions for detecting nucleic acids
WO2005079533A2 (en) * 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
JP2007523170A (ja) * 2004-02-19 2007-08-16 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法および装置
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
JP4866848B2 (ja) * 2004-06-30 2012-02-01 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルス（ｆｉｖ）のｅｎｖタンパク質のｖ３領域に由来するペプチドの使用を含むｆｉｖを検出するための方法および装置
CA2570610A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2006026248A1 (en) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
KR100780405B1 (ko) 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 알파 나선형 펩티드를 이용한 ｒｎａ 특이적 결합 펩티드탐색 방법
US20070134685A1 (en) * 2005-09-06 2007-06-14 Invitrogen Corporation Control of chemical modification
CN103784937B (zh) 2005-09-16 2017-04-26 科内尔研究基金会 用于减少cd36表达的方法
US20100184643A1 (en) * 2006-08-22 2010-07-22 University Of Virginia Patent Foundation Methods and Compounds Regulating the Erythroid Response to Iron Deficiency
JP2010501200A (ja) * 2006-08-25 2010-01-21 デューク・ユニヴァーシティ ｍｉｃｒｏＲＮＡの内在性ｍＲＮＡ標的のインビボでの同定のための方法
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
CN101711154A (zh) * 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
ES2559859T3 (es) 2007-05-16 2016-02-16 The Brigham And Women's Hospital, Inc. Tratamiento de sinucleinopatías
US8901487B2 (en) 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US20110033850A1 (en) * 2007-09-14 2011-02-10 Agris Paul F Compositions and methods for the identification of inhibitors of retroviral infection
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2232258A4 (de) * 2007-12-05 2011-01-05 Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services Verbesserte virale proteinquantifizierung und impfstoffqualitätskontrolle damit
US8673884B2 (en) * 2008-02-05 2014-03-18 Versitech Limited Anti-influenza compounds
JP5453320B2 (ja) 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
EP2342339A4 (de) * 2008-09-29 2012-06-06 Trana Discovery Inc Screening-verfahren zur identifizierung spezifischer staphylococcus aureus-inhibitoren
CA2741629C (en) 2008-10-27 2022-07-05 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
EP3653763A1 (de) 2009-02-13 2020-05-20 X-Chem, Inc. Verfahren zur erstellung und durchsuchung von dna-codierten bibliotheken
JP2012521355A (ja) 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
EP2429530B1 (de) 2009-05-14 2018-11-07 The General Hospital Corporation (s)-meclozin zur behandlung von ischämischen reperfusions-schäden
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
EP3292868A1 (de) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Verfahren und zusammensetzungen zur prävention oder behandlung ophthalmischer leiden
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
EP2553452B1 (de) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Nachweis des felinen immundefizienzvirus
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP3034625B1 (de) 2010-10-21 2017-10-04 Advanced Cell Diagnostics, Inc. Hochsensitives verfahren für den in-situ-nachweis von nukleinsäuren
WO2012058616A2 (en) * 2010-10-28 2012-05-03 Whitehead Institute For Biomedical Research Engineered kinetochores and uses thereof
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
WO2013085572A2 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
CA2847664C (en) 2011-09-05 2021-08-31 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of leber congenital amaurosis
DK2748357T3 (en) 2011-09-07 2018-07-16 X Chem Inc Methods for labeling DNA-encoded libraries
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
ES2907250T3 (es) 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
EP2836514A4 (de) 2012-04-13 2015-12-30 Childrens Medical Center Tiki-inhibitoren
CA2879018A1 (en) 2012-07-13 2014-01-16 X-Chem, Inc. Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
US9738623B2 (en) 2012-08-06 2017-08-22 The General Hospital Corporation Curcumin analogs
WO2014060483A1 (en) 2012-10-17 2014-04-24 Spatial Transcriptomics Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
CA2904350A1 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Glycine, mitochondrial one-carbon metabolism, and cancer
CN105431524B (zh) 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 用于降低肿瘤细胞的免疫抑制的方法和组合物
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US9757477B2 (en) 2013-09-06 2017-09-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
EP3152321B1 (de) 2014-06-05 2024-11-13 The Brigham and Women's Hospital, Inc. Diagnose und behandlung von invasiver aspergillose
US10131910B2 (en) 2014-07-10 2018-11-20 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of Usher syndrome type 2
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EP4282977B1 (de) 2015-04-10 2024-06-05 10x Genomics Sweden AB Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
KR102368920B1 (ko) 2016-04-25 2022-02-28 프로큐알 테라퓨틱스 Ⅱ 비.브이. 안 질환 치료용 올리고뉴클레오타이드
EP3454944B1 (de) 2016-05-13 2022-07-13 The Brigham and Women's Hospital, Inc. Flüchtige metabolitprofile zur diagnose und behandlung von mucorales-pilzen
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
CN109690294A (zh) * 2016-07-04 2019-04-26 塞尔图股份有限公司 用于测定转染的装置和方法
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
WO2018071519A1 (en) 2016-10-11 2018-04-19 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of fusariosis and scedosporiosis
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3688187A4 (de) * 2017-09-25 2021-09-29 Skyhawk Therapeutics, Inc. Verfahren und zusammensetzungen zum screening und identifizieren von spleissmodulatoren
EP3700527A4 (de) 2017-10-25 2021-03-10 Children's Medical Center Corporation Papd5-inhibitoren und verfahren zur verwendung davon
CR20200545A (es) 2018-05-15 2020-12-17 Lundbeck La Jolla Research Center Inc Inhibidores magl
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
WO2020123311A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Resolving spatial arrays using deconvolution
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
PT3921026T (pt) 2019-02-07 2024-03-22 Massachusetts Gen Hospital Carotenoides c50 para o tratamento ou a prevenção da náusea
WO2020212439A1 (en) * 2019-04-16 2020-10-22 F. Hoffmann-La Roche Ag Small molecule screening cellular assay using modified beads
EP3959197A4 (de) 2019-04-24 2022-10-12 Children's Medical Center Corporation Papd5-inhibitoren und verfahren zur verwendung davon
CN114174330B (zh) 2019-05-28 2025-01-17 总医院公司 Apoe抗体、融合蛋白及其用途
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
EP4025711A2 (de) 2019-11-08 2022-07-13 10X Genomics, Inc. Erhöhung der spezifität einer analytbindung
EP4055185A1 (de) 2019-11-08 2022-09-14 10X Genomics, Inc. Räumlich markierte analytfänger für analyt-multiplexing
CN115135984B (zh) 2019-12-23 2025-12-23 10X基因组学有限公司 可逆固定试剂及其使用方法
DK3891300T3 (da) 2019-12-23 2023-05-22 10X Genomics Inc Fremgangsmåder til rumlig analyse ved anvendelse af rna-template-ligering
US12241890B2 (en) 2019-12-23 2025-03-04 10X Genomics, Inc. Methods for generating barcoded nucleic acid molecules using fixed cells
US12365942B2 (en) 2020-01-13 2025-07-22 10X Genomics, Inc. Methods of decreasing background on a spatial array
US12405264B2 (en) 2020-01-17 2025-09-02 10X Genomics, Inc. Electrophoretic system and method for analyte capture
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US12129516B2 (en) 2020-02-07 2024-10-29 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
ES3014967T3 (en) 2020-04-22 2025-04-28 10X Genomics Inc Methods for spatial analysis using targeted rna depletion
US12416603B2 (en) 2020-05-19 2025-09-16 10X Genomics, Inc. Electrophoresis cassettes and instrumentation
EP4414459B1 (de) 2020-05-22 2025-09-03 10X Genomics, Inc. Simultane räumlich-zeitliche messung der genexpression und der zellaktivität
EP4153776B1 (de) 2020-05-22 2025-03-05 10X Genomics, Inc. Räumliche analyse zur erkennung von sequenzvarianten
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
EP4158054B1 (de) 2020-06-02 2025-04-16 10X Genomics, Inc. Räumliche transkriptomik für antigenrezeptoren
US12265079B1 (en) 2020-06-02 2025-04-01 10X Genomics, Inc. Systems and methods for detecting analytes from captured single biological particles
EP4025692A2 (de) 2020-06-02 2022-07-13 10X Genomics, Inc. Nukleinsäure-bibliotheksverfahren
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
EP4421186B1 (de) 2020-06-08 2025-08-13 10X Genomics, Inc. Verfahren zur bestimmung eines chirurgischen randes und verfahren zur verwendung davon
WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021252747A1 (en) 2020-06-10 2021-12-16 1Ox Genomics, Inc. Fluid delivery methods
US12435363B1 (en) 2020-06-10 2025-10-07 10X Genomics, Inc. Materials and methods for spatial transcriptomics
EP4450639B1 (de) 2020-06-25 2025-10-15 10X Genomics, Inc. Räumliche analyse der dna-methylierung
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US12209280B1 (en) 2020-07-06 2025-01-28 10X Genomics, Inc. Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US12553898B1 (en) 2020-08-10 2026-02-17 10X Genomics, Inc. Fluorescent hybridization of antibody-oligonucleotide for multiplexing and signal amplification
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
EP4214678B1 (de) 2020-09-18 2024-11-06 10X Genomics, Inc. Probenhandhabungsvorrichtung und bildregistrierungsverfahren
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2022178267A2 (en) 2021-02-19 2022-08-25 10X Genomics, Inc. Modular assay support devices
WO2022198068A1 (en) 2021-03-18 2022-09-22 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
EP4305196B1 (de) 2021-04-14 2025-04-02 10X Genomics, Inc. Verfahren zur messung der fehllokalisierung eines analyten
WO2022236054A1 (en) 2021-05-06 2022-11-10 10X Genomics, Inc. Methods for increasing resolution of spatial analysis
EP4582555A3 (de) 2021-06-03 2025-10-22 10X Genomics, Inc. Verfahren, zusammensetzungen, kits und systeme zur verbesserung der analyterfassung zur räumlichen analyse
US12553805B2 (en) 2021-08-02 2026-02-17 10X Genomics, Inc. Methods of preserving a biological sample
EP4196605B1 (de) 2021-09-01 2024-12-04 10X Genomics, Inc. Verfahren zur blockierung einer erfassungssonde auf einer räumlichen anordnung
WO2023086880A1 (en) 2021-11-10 2023-05-19 10X Genomics, Inc. Methods, compositions, and kits for determining the location of an analyte in a biological sample
WO2023102118A2 (en) 2021-12-01 2023-06-08 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
EP4441711A1 (de) 2021-12-20 2024-10-09 10X Genomics, Inc. Selbsttest für eine pathologie-/histologie-objektträgerbildgebungsvorrichtung
WO2023183886A2 (en) * 2022-03-23 2023-09-28 Duke University Compositions for and methods of modulating rna stability
DE102022124232A1 (de) 2022-09-21 2024-03-21 Carl von Ossietzky Universität Oldenburg, Körperschaft des öffentlichen Rechts Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms
EP4482979B1 (de) 2022-11-09 2025-10-01 10X Genomics, Inc. Verfahren, zusammensetzungen und kits zur bestimmung der position mehrerer analyten in einer biologischen probe

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
EP0232967B1 (de) 1986-01-10 1993-04-28 Amoco Corporation Kompetitiver homogener Test
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
AU3249793A (en) * 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
ES2289194T3 (es) 1993-05-27 2008-02-01 Aventis Pharmaceuticals Inc. Bibliotecas en fase solida codificadas, segregadas topologicamente.
WO1995005389A1 (en) * 1993-08-18 1995-02-23 The Board Of Trustees Of The Leland Stanford Junior University Sequence-specific glycoconjugate transcriptional antagonists
EP0739486A4 (de) * 1994-01-13 1998-09-09 Univ Columbia Synthetische rezeptoren, bibliotheken und ihre verwendung
US5712096A (en) * 1994-08-23 1998-01-27 University Of Massachusetts Medical Center Oligoribonucleotide assays for novel antibiotics
US5627210A (en) * 1995-02-06 1997-05-06 Chiron Corporation Branched combinatorial libraries
US5593835A (en) * 1995-05-12 1997-01-14 President And Fellows Of Harvard College Methods and kits for RNA binding compounds
WO1997009342A1 (en) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for rna
US5666341A (en) * 1995-09-18 1997-09-09 Matsushita Electric Industrial Co., Ltd. Data detection apparatus
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6004749A (en) 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US5843995A (en) * 1997-07-07 1998-12-01 University Of Medicine And Dentistry Of New Jersey Inhibition of HIV-1 replication using oligocarbamate derivatives
JP2001521759A (ja) * 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド ヒトアミロイド前駆体タンパク質遺伝子の翻訳エンハンサーエレメント

Also Published As

Publication number Publication date
CA2386239A1 (en) 2001-04-12
US6875736B2 (en) 2005-04-05
DE60042338D1 (de) 2009-07-16
US20030153523A1 (en) 2003-08-14
EP1218544A4 (de) 2005-05-25
JP2003511045A (ja) 2003-03-25
JP2003511362A (ja) 2003-03-25
WO2001025188A1 (en) 2001-04-12
CA2386540A1 (en) 2001-04-12
US20050221368A1 (en) 2005-10-06
AU7856600A (en) 2001-05-10
US6583309B1 (en) 2003-06-24
WO2001025486A1 (en) 2001-04-12
EP1226115A4 (de) 2006-03-15
AU7855900A (en) 2001-05-10
EP1218544A1 (de) 2002-07-03
EP1226115A1 (de) 2002-07-31
EP2071036A2 (de) 2009-06-17
EP1218544B1 (de) 2009-06-03
EP2071036A3 (de) 2009-09-09
US6503713B1 (en) 2003-01-07
US6420591B1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
ATE432993T1 (de) Tar rna bindende peptide
TW200506066A (en) Modulation of protein functionalities
ATE470150T1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
JP2002507748A5 (de)
DE60335000D1 (de) In vitro peptid-expressionsbank
US20130309689A1 (en) Methods and reagents for biomolecule labeling, enrichment and gentle elution
DK1512015T3 (da) Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
Miao et al. Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: a biosensor-surface plasmon resonance assay
EP1147123A4 (de) Neuartige geruchsrezeptoren in drosophila
EP3137898A2 (de) Auf veränderungen in proteinoberflächen gerichteter fluoreszierender molekularsensor und verfahren zur verwendung davon
DE69939275D1 (de) Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
Fan et al. Rapid fluorescence immunoassay of benzo [a] pyrene in mainstream cigarette smoke based on a dual-functional antibody–DNA conjugate
DE69924147D1 (de) Floureszenzintensitäts-test für eine protein- oder peptidbindung an nukleinsäuren
Silva et al. Protein purification by aminosquarylium cyanine dye‐affinity chromatography
Kriegelsteinová et al. Copper‐free solid‐phase synthesis of triazolo [1, 5‐a][1, 4] diazepin‐6‐ones
EA200701578A1 (ru) Способ конъюгирования молекул, содержащих аминотиол, к носителям
Arnusch et al. Solid phase synthesis of vancomycin mimics
Katritzky et al. N‐Fmoc‐protected (α‐dipeptidoyl) benzotriazoles for efficient solid‐phase peptide synthesis by segment condensation
Nakamura et al. Tailored synthesis of 162‐residue S‐monoglycosylated GM2‐activator protein (GM2AP) analogues that allows facile access to a protein library
Giron et al. Cysteine‐reactive covalent capture tags for enrichment of cysteine‐containing peptides
Nishio et al. Structural differences between myofibrillar protein, paratropomyosin, and tropomyosin as revealed by high‐performance liquid chromatography
US20090130769A1 (en) Novel Cross-Linkers For Obtaining Structure Information On Molecule Complexes
Graça et al. Ethylenediamine-derived chromatographic ligand to separate BSA, lysozyme, and RNase a
US20240409506A1 (en) Compositions and Methods for Labeling of Thioethers
Olsen et al. Identification of the amino acids of human serum albumin involved in the reaction with the naproxen acyl coenzyme A thioester using liquid chromatography combined with fluorescence and mass spectrometric detection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties